BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10368700)

  • 21. A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits.
    Minatoguchi S; Arai M; Uno Y; Kariya T; Nishida Y; Hashimoto K; Kawasaki M; Takemura G; Fujiwara T; Fujiwara H
    Br J Pharmacol; 1999 Dec; 128(8):1667-72. PubMed ID: 10588921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus.
    Yokoyama H; Kannno S; Ishimura I; Node K
    Metabolism; 2007 Nov; 56(11):1458-63. PubMed ID: 17950094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of alpha-inhibitors on blood glucose and insulin levels.
    Laube H; Federlin K; Hillebrand I
    Adv Exp Med Biol; 1988; 246():287-93. PubMed ID: 3074658
    [No Abstract]   [Full Text] [Related]  

  • 24. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics.
    Standl E; Schernthaner G; Rybka J; Hanefeld M; Raptis SA; Naditch L
    Diabetes Res Clin Pract; 2001 Mar; 51(3):205-13. PubMed ID: 11269893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of miglitol, an anti-diabetic drug, and nicorandil markedly reduces myocardial infarct size through opening the mitochondrial K(ATP) channels in rabbits.
    Minatoguchi S; Wang N; Uno Y; Arai M; Hashimoto K; Hashimoto Y; Chen XH; Takemura G; Fujiwara H
    Br J Pharmacol; 2001 Aug; 133(7):1041-6. PubMed ID: 11487514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
    Axen KV; Li X; Sclafani A
    Obes Res; 1999 Jan; 7(1):83-9. PubMed ID: 10023734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of type 2 diabetes mellitus with the alpha-glucosidase inhibitor Miglitol in the doctor's office].
    Fehmann HC
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():55-61. PubMed ID: 15700487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current status of the treatment of type 2 diabetes mellitus. Alpha-glucosidase inhibitors].
    Blicklé JF; Andres E; Brogard JM
    Rev Med Interne; 1999 Aug; 20 Suppl 3():379s-383s. PubMed ID: 10480189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.
    Pagano G; Marena S; Corgiat-Mansin L; Cravero F; Giorda C; Bozza M; Rossi CM
    Diabete Metab; 1995 Jun; 21(3):162-7. PubMed ID: 7556806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of miglitol administration to non-insulin-dependent diabetic rats.
    Tormo MA; Ropero MF; Nieto M; Martinez IM; Campillo JE
    Gen Pharmacol; 1998 Jan; 30(1):125-9. PubMed ID: 9457493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients.
    Johnston PS; Coniff RF; Hoogwerf BJ; Santiago JV; Pi-Sunyer FX; Krol A
    Diabetes Care; 1994 Jan; 17(1):20-9. PubMed ID: 8112185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving management of type 2 diabetes mellitus: 1. alpha-Glucosidase inhibitors.
    Kuritzky L; Samraj G; Quillen DM
    Hosp Pract (1995); 1999 Sep; 34(10):43-6. PubMed ID: 10901748
    [No Abstract]   [Full Text] [Related]  

  • 33. Miglitol, a new alpha-glucosidase inhibitor.
    Sels JP; Huijberts MS; Wolffenbuttel BH
    Expert Opin Pharmacother; 1999 Nov; 1(1):149-56. PubMed ID: 11249557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
    Scheen AJ
    Drugs; 2003; 63(10):933-51. PubMed ID: 12699398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type-2 diabetics.
    Katsilambros N; Philippides P; Toskas A; Protopapas J; Frangaki D; Marangos M; Siskoudis P; Anastasopoulou K; Xefteri H; Hillebrand I
    Arzneimittelforschung; 1986 Jul; 36(7):1136-8. PubMed ID: 3533089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
    Heinz G; Komjati M; Korn A; Waldhäusl W
    Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Miglitol: assessment of its role in the treatment of patients with diabetes mellitus.
    Campbell LK; Baker DE; Campbell RK
    Ann Pharmacother; 2000 Nov; 34(11):1291-301. PubMed ID: 11098345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The acute effects of glucosidase inhibition on post-meal glucose increments in insulin-dependent diabetics.
    Wing J; Kalk WJ; Berzin M; Diamond TH; Griffiths RF; Smit AM; Osler CE
    S Afr Med J; 1990 Mar; 77(6):286-8. PubMed ID: 2180090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Miglitol in the treatment of the insulin-dependent diabetic patient. Improved metabolic control and excellent tolerance].
    Rinninger F; Lotz N; Hillebrand I; Bachmann W
    Fortschr Med; 1987 Jul; 105(22):435-8. PubMed ID: 3653827
    [No Abstract]   [Full Text] [Related]  

  • 40. The anti-diabetic drug miglitol is protective against anginal ischaemia through a mechanism independent of regional myocardial blood flow in the dog.
    Uno Y; Minatoguchi S; Arai M; Wang N; Chen XH; Hashimoto K; Lu C; Takemura G; Fujiwara H
    Clin Exp Pharmacol Physiol; 2005 Oct; 32(10):805-10. PubMed ID: 16173940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.